KarenRuthRabinMDPhD
Pediatric Hematology & Oncology • Houston, TXProfessor, Pediatrics, Baylor College of Medicine
Dr. Rabin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1102 Bates Ave Suite 750.00
Texas Childrens Cancer Center
Houston, TX 77030Phone+1 832-822-4242Fax+1 832-825-1206
Summary
- Dr. Karen Rabin is a medical professional based in Houston, TX, specializing in Pediatric Hematology & Oncology. She completed her Pediatric Hematology/Oncology fellowship at Lucile Packard Children's Hospital/Stanford University School of Medicine in 2004, following the completion of her Pediatrics residency at the University of California San Francisco School of Medicine in 2001. Dr. Rabin is Director of the Leukemia Program at Texas Children's Cancer Center and has significant experience in hematologic malignancies, particularly acute lymphoblastic leukemia (ALL). She has contributed to pediatric oncology research through numerous publications and has been involved in multiple clinical trials focused on therapies for childhood ALL.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
University of California (San Francisco)Residency, Pediatrics, 1998 - 2001- University of California San Francisco School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2000 - Present
TX State Medical License 2006 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
Publications & Presentations
PubMed
- 33 citationsPRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.Ingrid M. Ariës, Kimberly Bodaar, Salmaan Karim, Triona Ni Chonghaile, Laura Hinze
The Journal of Experimental Medicine. 2018-12-03 - 204 citationsTargetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.Shalini C. Reshmi, Richard C. Harvey, Kathryn G. Roberts, Eileen Stonerock, Amy Smith
Blood. 2017-06-22 - 107 citationsThe TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.Rayne H. Rouce, Hila Shaim, Takuya Sekine, Gerrit Weber, Brandon Ballard
Leukemia. 2016-04-01
Abstracts/Posters
- Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic ...Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Genomic Landscape of Childhood Acute Lymphoblastic LeukemiaKaren R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Pa...Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Dasatinib Superior to Imatinib in Pediatric ALLJanuary 16th, 2020
Novel Approach Identifies Factors Linked to Poor Treatment Outcomes in Acute Lymphoblastic LeukemiaOctober 24th, 2019
Dasatinib Beats Imatinib in Childhood LeukemiaMarch 14th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
